TITLE

Medical oncology

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS60
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Can antifungal prophylaxis with fluconazole (F) reduce pain associated with superficial fungal infection (SFI)?,' by E.J. Bow et al.
ACCESSION #
9708236653

 

Related Articles

  • Pharmacists help fight upsurge in fungal infections. Lieder, Tzipora R. // Drug Topics;2/18/2002, Vol. 146 Issue 4, p6 

    Deals with the efforts of pharmacists to develop treatment for fungal infections. Approval of the intravenous Cancidas caspofungin acetate from Merck; Implication of appropriate dosing of antifungals; Variation in the duration of antifungal therapy.

  • Identification of Antifungal Agents Using Combinatorial Approach: An Overview$. Gupta, P.; Singh, S.K.; Srinivasan, T.; Kundu, B. // Current Medicinal Chemistry - Anti-Infective Agents;Jun2003, Vol. 2 Issue 2, p113 

    During the past two-decades the frequencies and type of life threatening fungal infection have increased dramatically among cancer patients, transplant recipients, patients with AIDS and patients receiving broad-spectrum antibiotic or parental nutrition. There has been a constant effort to...

  • Lamisil spray available in Canada to treat fungal skin conditions.  // Dermatology Times;Jul99, Vol. 20 Issue 7, p7 

    Introduces Lamisil spray for treatment of fungal skin conditions manufactured by Novartis Pharmaceuticals Canada Inc. in Toronto Ontario.

  • Monthly itraconazole prevents recurrence of pityriasis versicolor. Guttman, Cheryl // Dermatology Times;Apr2002 Supplement 2, Vol. 23 Issue 4, pS4 

    Investigates the efficacy of itraconazole for the treatment of pityriasis versicolor in Gothenburg, Sweden. Safety option for preventing relapse of the fungal infection; Potency of the regimen against the Malassezia species causing the infection; Concentration of itraconazole to inhibit fungal...

  • Immunocompromised still a fungal challenge. Guttman, Cheryl // Dermatology Times;Apr2002 Supplement 2, Vol. 23 Issue 4, pS12 

    Focuses on the evolution of immunocompromised hosts in fungal infections. Emergence of causative pathogens; Availability of antifungal drug choices for management of diseases; Number of patients with transplant-associated immunosuppression.

  • Intraconazole use covers various inflammatory diseases. Moyer, Paula // Dermatology Times;Sep2002, Vol. 23 Issue 9, p22 

    Examines the use of itraconazole in treating various inflammatory diseases. Response of disorders with no mycotic components to the drug; Reduction of signs and symptoms of fungal infections due to drug administration; Role of Malassezia species in the pathogenesis of several inflammatory diseases.

  • Fungal infections. Jordan, Andy // Pulse;7/7/2003, Vol. 63 Issue 27, p53 

    Presents advice in treating fungal infections. Causes of athlete's foot; Use of over-the-counter miconazole cream to stop the spread of the rashes; Reaction of the body to fungus.

  • Efflux Pump Inhibitors: Key to. Jack More Effective Antifungal Treatment?, David // Dermatology Times;Jul98, Vol. 19 Issue 7, p26 

    Considers the effectiveness of efflux pump inhibitors in the treatment of patients which are resistant to antifungal drugs. Physiological significance of efflux pump inhibitors; Therapeutic benefits of efflux; Concerns on issues related to patients with fungal infections.

  • The Cost of Treating Systemic Fungal Infections. van Gool, R. // Drugs;Jan2001 Supplement, Vol. 61 Issue 1, p49 

    The increasing incidence of systemic fungal infections and rising medical costs have highlighted the need for an economic appraisal of antifungal agents to determine the most cost-effective therapeutic option. Cost savings derived from the prophylactic or empirical use of antifungal agents have...

  • Current Management of Fungal Infections. Meis, J.F.G.M.; Verweij, P.E. // Drugs;Jan2001 Supplement, Vol. 61 Issue 1, p13 

    The management of superficial fungal infections differs significantly from the management of systemic fungal infections. Most superficial infections are treated with topical antifungal agents, the choice of agent being determined by the site and extent of the infection and by the causative...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics